Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal
about
Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group StudyA phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a GynecologicA phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer.The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma.Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma.Aged mice repeatedly injected with plasma from young mice: a survival study.Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograftThree ongoing intraperitoneal chemotherapy trials in ovarian cancer.Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.Intraperitoneal injection is not always a suitable alternative to intravenous injection for radiotherapyIntraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin.Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy.Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer.Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer.Preventing recurrence of diffuse malignant peritoneal mesothelioma.Targeted nanoparticle for head and neck cancers: overview and perspectives.New poly(ester-amide) copolymers modified with polyether (PEAE) for anticancer drug encapsulation.Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.Mathematical modeling of intraperitoneal drug delivery: simulation of drug distribution in a single tumor nodule.Potential microRNA-related Targets for Therapeutic Intervention with Ovarian Cancer Metastasis.Pharmacokinetic delivery and metabolizing rate of nicardipine incorporated in hydrophilic and hydrophobic cyclodextrins using two-compartment mathematical model.
P2860
Q30411910-A69D94D6-E3A0-43D6-A378-BDA1368DDF6CQ30418953-2B0156E1-3A0D-4E1D-ADB7-B1BF4B3CF32BQ33393909-175A55C9-E509-42A4-BC24-3B9180F02090Q33396173-5EDB57A3-3043-4FE6-AE1E-5D8B61C9241AQ33419382-DBDCCCB9-B421-4F23-B970-81994D3FFCD3Q33419612-85C38B86-1FF6-4E04-AC94-8467A49535A8Q34431523-5907822F-CC23-430B-92DE-581E8230CA06Q35766191-BB6B7BEF-AD34-4D6F-AD0E-40AB517072CAQ35886086-E34AB356-F8DF-40BD-8301-5BBF5673F417Q36607749-6D7E345D-C604-4119-A4E8-13C320CF6F25Q36842135-8713F775-D780-449A-9060-A3276E80FC8AQ37202777-76E84A34-B912-4EAF-B421-3C904A096793Q37230288-76428168-9ED3-4811-8A71-69C413707F74Q37368932-9CB59739-C409-42E1-A567-3E2E4AEBF660Q37993908-558324B0-E0E2-4393-BC58-B8B035C96E56Q38040628-AE90B7BB-5A8D-48D6-86DA-58671379BAD3Q38126548-5C952907-D67E-45E2-A0D1-3169C5A21A5EQ38769834-744C1E8F-ED43-40FF-ADC5-C763018329A3Q38917015-19097D30-882D-49C3-9B9B-690E59EDA88FQ39226270-52C70C22-30A9-4CF1-A2DF-89CF3A2DF01AQ39321451-2F1727F9-2BBD-4E49-B7C9-0658B2F6E472Q46401419-60398BEE-58E2-4BA4-B28C-9FAFC07B6B58Q47978622-FABE8830-C7F7-49D2-8552-76DC15A6C78CQ49593669-4B1AAB95-D2DE-45C3-BD10-6287039F158BQ51126048-44F5BBF9-4BFC-46C1-A77D-26C3646091DB
P2860
Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Intraperitoneal carboplatin in ...... al model after intraperitoneal
@en
Intraperitoneal carboplatin in ...... al model after intraperitoneal
@nl
type
label
Intraperitoneal carboplatin in ...... al model after intraperitoneal
@en
Intraperitoneal carboplatin in ...... al model after intraperitoneal
@nl
prefLabel
Intraperitoneal carboplatin in ...... al model after intraperitoneal
@en
Intraperitoneal carboplatin in ...... al model after intraperitoneal
@nl
P2093
P1433
P1476
Intraperitoneal carboplatin in ...... al model after intraperitoneal
@en
P2093
Eriko Aotani
Hiroaki Itamochi
Ichiro Kohno
Junzo Kigawa
Keiichi Fujiwara
Naoki Terakawa
Sankai Gynecology Study Group (SGSG)
Shoji Nagao
Yasunari Miyagi
P304
P356
10.1016/J.YGYNO.2005.06.055
P407
P577
2005-08-10T00:00:00Z